Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTARA THERAPEUTICS, INC.

(TARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Protara Therapeutics, Inc.
Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase - Recombinant Human elastase. The Company's lead product pipeline is TARA 002 for the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).

Number of employees : 29 people.
Managers
Name Title Age Since
Jesse Shefferman President, Chief Executive Officer & Director 48 2017
Blaine T. Davis Chief Financial Officer & Secretary 46 2020
Jacqueline Zummo, Dr. Chief Scientific Operations Officer & Senior VP 39 2021
Jathin Bandari, Dr. Chief Medical Officer & Vice President - 2021
Luke M. Beshar Chairman 62 2018
Richard S. Levy, Dr. Independent Director 62 2020
Gregory P. Sargen Independent Director 55 2019
Roger J. Garceau, Dr. Independent Director 66 2019
Michael E. Solomon, Dr. Independent Director 50 2018
Barry Flannelly, Dr. Independent Director 62 2020
Members of the board
Name Title Age Since
Luke M. Beshar Chairman 62 2018
Richard S. Levy, Dr. Independent Director 62 2020
Gregory P. Sargen Independent Director 55 2019
Roger J. Garceau, Dr. Independent Director 66 2019
Michael E. Solomon, Dr. Independent Director 50 2018
Jesse Shefferman President, Chief Executive Officer & Director 48 2017
Barry Flannelly, Dr. Independent Director 62 2020
Cynthia Smith Independent Director 51 2021
Jane Huang Director 47 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 11,235,731 9,100,623 81.0% 0 0.0% 81.0%
Stock B 0 8,027 0 0.0% 0 0.0%
Shareholders
NameEquities%
Opaleye Management, Inc. 2,589,353 23.0%
Jesse Shefferman 797,705 7.10%
Deerfield Management Company LP 782,670 6.97%
Rock Springs Capital Management LP 693,542 6.17%
Randall Marshall 585,600 5.21%
Ikarian Capital LLC 479,995 4.27%
OrbiMed Advisors Private Equity 450,000 4.01%
The Vanguard Group, Inc. 433,154 3.86%
Farallon Capital Management LLC 425,000 3.78%
Perceptive Advisors LLC 421,641 3.75%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Protara Therapeutics, Inc.